LU87033A1 - Nouvelle association medicamenteuse - Google Patents

Nouvelle association medicamenteuse Download PDF

Info

Publication number: LU87033A1
Authority: LU; Luxembourg
Prior art keywords: tizanidine; ibuprofen; composition according; pharmaceutically acceptable; treatment
Prior art date: 1986-11-03

Application number

LU87033A

Other languages

English (en)

French (fr)

Original Assignee

Sandoz Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-11-03

Filing date

1987-10-30

Publication date

1988-05-03

1987-10-30 Application filed by Sandoz Sa filed Critical Sandoz Sa

1988-05-03 Publication of LU87033A1 publication Critical patent/LU87033A1/fr

Links

239000002547 new drug Substances 0.000 title description 7
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical class CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 28
229960001680 ibuprofen Drugs 0.000 claims description 27
XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 claims description 22
238000011282 treatment Methods 0.000 claims description 22
229960000488 tizanidine Drugs 0.000 claims description 21
239000000203 mixture Substances 0.000 claims description 13
150000003839 salts Chemical class 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 7
208000007101 Muscle Cramp Diseases 0.000 claims description 4
208000005392 Spasm Diseases 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
230000004968 inflammatory condition Effects 0.000 claims description 2
150000001875 compounds Chemical class 0.000 claims 4
230000000694 effects Effects 0.000 description 16
208000002193 Pain Diseases 0.000 description 14
230000036407 pain Effects 0.000 description 11
239000003826 tablet Substances 0.000 description 9
238000012360 testing method Methods 0.000 description 9
230000000202 analgesic effect Effects 0.000 description 6
239000004480 active ingredient Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
241000700159 Rattus Species 0.000 description 3
208000008765 Sciatica Diseases 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000000890 drug combination Substances 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
230000033001 locomotion Effects 0.000 description 3
239000003158 myorelaxant agent Substances 0.000 description 3
208000004998 Abdominal Pain Diseases 0.000 description 2
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
206010028813 Nausea Diseases 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000002585 base Substances 0.000 description 2
238000000876 binomial test Methods 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
239000008298 dragée Substances 0.000 description 2
201000006549 dyspepsia Diseases 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
230000008693 nausea Effects 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
VVJYUAYZJAKGRQ-UHFFFAOYSA-N 1-[4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C(O)C1 VVJYUAYZJAKGRQ-UHFFFAOYSA-N 0.000 description 1
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
108010082126 Alanine transaminase Proteins 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
101000856500 Bacillus subtilis subsp. natto Glutathione hydrolase proenzyme Proteins 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010008334 Cervicobrachial syndrome Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000009386 Experimental Arthritis Diseases 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
208000008930 Low Back Pain Diseases 0.000 description 1
241000186359 Mycobacterium Species 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
ZWUKMNZJRDGCTQ-UHFFFAOYSA-N Tizanidine hydrochloride Chemical compound Cl.ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 ZWUKMNZJRDGCTQ-UHFFFAOYSA-N 0.000 description 1
206010044074 Torticollis Diseases 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940124575 antispasmodic agent Drugs 0.000 description 1
-1 antispasmodics Substances 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
229940005530 anxiolytics Drugs 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
238000013475 authorization Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000004820 blood count Methods 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229960005069 calcium Drugs 0.000 description 1
PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
238000000151 deposition Methods 0.000 description 1
230000003205 diastolic effect Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000013265 extended release Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
210000004394 hip joint Anatomy 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
208000014674 injury Diseases 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
210000002346 musculoskeletal system Anatomy 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
208000027753 pain disease Diseases 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000009519 pharmacological trial Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000003068 static effect Effects 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000029305 taxis Effects 0.000 description 1
229960002388 tizanidine hydrochloride Drugs 0.000 description 1
230000008733 trauma Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
229940045136 urea Drugs 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Anesthesiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LU87033A 1986-11-03 1987-10-30 Nouvelle association medicamenteuse LU87033A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE3637240		1986-11-03
DE3637240		1986-11-03

Publications (1)

Publication Number	Publication Date
LU87033A1 true LU87033A1 (fr)	1988-05-03

Family

ID=6312966

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU87033A LU87033A1 (fr)	1986-11-03	1987-10-30	Nouvelle association medicamenteuse

Country Status (18)

Country	Link
JP (1)	JPS63132834A (da)
KR (1)	KR890007728A (da)
AU (1)	AU8057587A (da)
BE (1)	BE1000265A3 (da)
DD (1)	DD300508A5 (da)
DK (1)	DK574187A (da)
FR (1)	FR2605884B1 (da)
GB (1)	GB2197198A (da)
GR (1)	GR871678B (da)
HU (1)	HUT47849A (da)
IL (1)	IL84344A0 (da)
IT (1)	IT8748554A0 (da)
LU (1)	LU87033A1 (da)
NL (1)	NL8702523A (da)
PH (1)	PH23276A (da)
PT (1)	PT86061B (da)
SE (1)	SE8704240L (da)
ZA (1)	ZA878257B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5260337A (en) *	1992-07-29	1993-11-09	Merck & Co., Inc.	Ibuprofen-muscle relaxant combinations
US20040122065A1 (en) *	2002-11-12	2004-06-24	Lerner E. Itzhak	Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or buccally
TR200703092A1 (tr)	2007-05-08	2008-12-22	SANOVEL �LA� SAN. VE TiC. A.�.	Flurbiprofen ve kas gevşetici kombinasyonları
WO2013159151A1 (en) *	2012-04-27	2013-10-31	Troy Laboratories Pty Ltd	Combination meloxicam and xylazine therapy in animals
EP2977045A1 (en)	2014-07-21	2016-01-27	Sanovel Ilac Sanayi ve Ticaret A.S.	Zaltoprofen and muscle relaxant combinations
WO2016046189A1 (en)	2014-09-24	2016-03-31	Sanovel Ilac Sanayi Ve Ticaret A.S.	Loxoprofen and antispastic drug combinations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3012837A1 (de) *	1979-04-10	1980-10-30	Sandoz Ag	Analgetische und myotonolytische praeparate
GB2135884B (en) *	1983-03-09	1986-09-17	Sandoz Ltd	Analgesic preparations containing tizanidine and paracetamol
US4571400A (en) *	1984-12-18	1986-02-18	Belleview Pharmaceutical, Inc.	Dihydrocodeine/ibuprofen pharmaceutical compositions and method

1987
- 1987-10-22 NL NL8702523A patent/NL8702523A/nl not_active Application Discontinuation
- 1987-10-22 HU HU874740A patent/HUT47849A/hu unknown
- 1987-10-30 IT IT8748554A patent/IT8748554A0/it unknown
- 1987-10-30 FR FR878715185A patent/FR2605884B1/fr not_active Expired
- 1987-10-30 SE SE8704240A patent/SE8704240L/xx not_active Application Discontinuation
- 1987-10-30 BE BE8701237A patent/BE1000265A3/fr not_active IP Right Cessation
- 1987-10-30 LU LU87033A patent/LU87033A1/fr unknown
- 1987-10-30 GB GB08725538A patent/GB2197198A/en not_active Withdrawn
- 1987-11-02 IL IL84344A patent/IL84344A0/xx unknown
- 1987-11-02 DK DK574187A patent/DK574187A/da not_active Application Discontinuation
- 1987-11-02 KR KR870012244A patent/KR890007728A/ko not_active Withdrawn
- 1987-11-02 JP JP62278987A patent/JPS63132834A/ja active Pending
- 1987-11-02 GR GR871678A patent/GR871678B/el unknown
- 1987-11-02 DD DD308577A patent/DD300508A5/de unknown
- 1987-11-02 AU AU80575/87A patent/AU8057587A/en not_active Abandoned
- 1987-11-02 PT PT86061A patent/PT86061B/pt not_active IP Right Cessation
- 1987-11-03 PH PH36018A patent/PH23276A/en unknown
- 1987-11-03 ZA ZA878257A patent/ZA878257B/xx unknown

Also Published As

Publication number	Publication date
ZA878257B (en)	1989-06-28
SE8704240L (sv)	1988-05-04
IL84344A0 (en)	1988-04-29
DD300508A5 (de)	1992-06-17
NL8702523A (nl)	1988-06-01
PH23276A (en)	1989-06-23
GB2197198A (en)	1988-05-18
FR2605884A1 (fr)	1988-05-06
AU8057587A (en)	1988-05-05
GR871678B (en)	1988-03-03
JPS63132834A (ja)	1988-06-04
HUT47849A (en)	1989-04-28
GB8725538D0 (en)	1987-12-02
BE1000265A3 (fr)	1988-09-27
DK574187D0 (da)	1987-11-02
SE8704240D0 (sv)	1987-10-30
FR2605884B1 (fr)	1989-05-05
PT86061B (pt)	1990-11-07
IT8748554A0 (it)	1987-10-30
DK574187A (da)	1988-05-04
PT86061A (en)	1987-12-01
KR890007728A (ko)	1989-07-05

Publication	Publication Date	Title
EP1795194A2 (fr)	2007-06-13	Utilisation d'un antagoniste des récepteurs CB1 associé à un bêta3-agoniste pour la préparation de médicaments utiles pour traiter l'appétence
JP2001509173A (ja)	2001-07-10	胃腸リパーゼ阻害剤の使用
RS52907B (sr)	2014-02-28	Upotreba ace inhibitora za prevenciju kongestivne srčane insuficijencije
FR2904774A1 (fr)	2008-02-15	Composition pharmaceutique solide contenant une combinaison d'un agent regulateur de la motilite intestinale et d'un antiflatulent.
BE897355A (fr)	1983-11-14	Compositions analgestiques et anti-inflammatoires comprenant de l'ibuprofen
EP0866704A1 (fr)	1998-09-30	Utilisation de la 1-(2-napht-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
FR2837706A1 (fr)	2003-10-03	Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles
BE1007024A5 (fr)	1995-02-21	Compositions a activite agoniste des recepteurs analogues a 5ht1, selective.
BE1000265A3 (fr)	1988-09-27	Nouvelle association medicamenteuse.
EP1441723B1 (fr)	2007-05-02	Utilisation de l'irbesartan pour la prevention ou le traitement de l'hypertension pulmonaire
DE3785689T2 (de)	1993-08-19	Verwendung von prostaglandin-biosynthese-hemmer.
LU85242A1 (fr)	1984-11-14	Nouvelle association medicamenteuse
EP0966276B1 (fr)	2003-12-10	Utilisation d'agonistes des recepteurs beta-3 adrenergiques pour la preparation de medicaments cicatrisants
JPH08239327A (ja)	1996-09-17	慢性骨格筋疼痛の予防又は治療剤
CA1059913A (fr)	1979-08-07	Compositions pharmaceutiques
CA2684171C (fr)	2015-12-01	Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
JPH0680009B2 (ja)	1994-10-12	抗高血圧組み合わせ医薬
EP1115399B1 (fr)	2005-03-02	Utilisation d'une composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et l'indomethacine pour la fabrication d'un medicament pour traiter les glomerulonephrites chroniques
US20010056115A1 (en)	2001-12-27	Novel therapeutic method
EP0005733A1 (en)	1979-12-12	Pharmaceutical compositions for use in the treatment of diabetic nephropathy and method for preparing them
BE1007586A3 (fr)	1995-08-16	Produits pharmaceutiques.
CA1079195A (fr)	1980-06-10	Procede de preparation d'un nouveau medicament hypotenseur a action retardee
FR2551974A1 (fr)	1985-03-22	Preparation de dobutamine pour l'administration orale
CA1227136A (fr)	1987-09-22	Compositions pharmaceutiques contenant a titre de principe actif l'acide 4-(benzofuran-2-yl)4-oxo buten-2-oique et/ou de ses sels pharmaceutiquement acceptables
FR2733911A1 (fr)	1996-11-15	Composition pharmaceutique pour maladies renales ou cardio-vasculaires